Astrocytoma Clinical Trials

66 recruitingLast updated: June 18, 2026

There are 66 actively recruiting astrocytoma clinical trials across 27 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Astrocytoma Trials at a Glance

66 actively recruiting trials for astrocytoma are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 1 with 26 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running astrocytoma studies include Jasper Gerritsen, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse astrocytoma trials by phase

Treatments under study

About Astrocytoma Clinical Trials

Looking for clinical trials for Astrocytoma? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Astrocytoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Astrocytoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 66 trials

Recruiting
Phase 3

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Low-grade GliomaLow Grade AstrocytomaWHO Grade 2 Glioma+3 more
National Cancer Institute (NCI)170 enrolled132 locationsNCT04166409
Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 3

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Astrocytoma, IDH-Mutant, Grade 3
Alliance for Clinical Trials in Oncology408 enrolled75 locationsNCT07215910
Recruiting
Not Applicable

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

Optic pathway gliomaGliomaPilocytic Astrocytoma+4 more
St. Jude Children's Research Hospital74 enrolled2 locationsNCT04065776
Recruiting
Phase 1Phase 2

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled16 locationsNCT05765812
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled20 locationsNCT06161974
Recruiting
Phase 3

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

GliomaAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, Grade IV+5 more
Nuvation Bio Inc.365 enrolled55 locationsNCT05303519
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 4

Pediatric Long-Term Follow-up and Rollover Study

Neurofibromatosis Type 1GlioblastomaAnaplastic Astrocytoma+20 more
Novartis Pharmaceuticals165 enrolled55 locationsNCT03975829
Recruiting
Phase 1

A Study of 177Lu-PSMA-617 in People With Gliomas

GliomaGlioblastoma, IDH-wildtypeDiffuse Midline Glioma, H3 K27-Altered+3 more
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07223034
Recruiting

Loupe-Based Intraoperative Fluorescence Imaging

Glioblastoma MultiformeAnaplastic Astrocytoma
Guoqiang Yu30 enrolled1 locationNCT04780009
Recruiting
Phase 1Phase 2

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Glioblastoma MultiformeAnaplastic Astrocytoma
Northwell Health54 enrolled1 locationNCT01269853
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting
Phase 2

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

High Grade GliomaAnaplastic Astrocytoma
Ashish Shah33 enrolled1 locationNCT06264388
Recruiting

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

GliomasGlioma Glioblastoma MultiformeGliomas Harboring IDH1 and/or IDH2 Mutations+3 more
Xiangya Hospital of Central South University500 enrolled1 locationNCT07608003
Recruiting
Phase 3

Vorasidenib Maintenance for IDH Mutant Astrocytoma

IDH-mutant Grade 2 or 3 Astrocytoma
European Organisation for Research and Treatment of Cancer - EORTC468 enrolled33 locationsNCT06809322
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled20 locationsNCT06894979